Does use of alternative medicine delay treatment of head and neck cancer? A surveillance, epidemiology, and end results (SEER) cancer registry study

Head & Neck ◽  
2008 ◽  
Vol 30 (4) ◽  
pp. 446-454 ◽  
Author(s):  
Ikuko Kato ◽  
Anne Victoria Neale
Keyword(s):  
Head And Neck Cancer ◽  
Alternative Medicine ◽  
Head And Neck ◽  
Cancer Registry ◽  
Neck Cancer ◽  
Registry Study ◽  
End Results

scholarly journals Anesthetic Management of a Patient with Sustained Severe Metabolic Alkalosis and Electrolyte Abnormalities Caused by Ingestion of Baking Soda

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Jose Soliz ◽  
Jeffrey Lim ◽  
Gang Zheng
Keyword(s):  
Head And Neck Cancer ◽  
Alternative Medicine ◽  
Head And Neck ◽  
Neck Cancer ◽  
Metabolic Alkalosis ◽  
Anesthetic Management ◽  
Herbal Remedies ◽  
Anesthetic Care ◽  
Electrolyte Abnormalities

The use of alternative medicine is prevalent worldwide. However, its effect on intraoperative anesthetic care is underreported. We report the anesthetic management of a patient who underwent an extensive head and neck cancer surgery and presented with a severe intraoperative metabolic alkalosis from the long term ingestion of baking soda and other herbal remedies.

scholarly journals Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis

Cancer ◽  
2016 ◽  
Vol 123 (2) ◽  
pp. 283-293 ◽  
Author(s):  
Beth M. Beadle ◽  
Kai-Ping Liao ◽  
Sharon H. Giordano ◽  
Adam S. Garden ◽  
Katherine A. Hutcheson ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Intensity Modulated Radiation Therapy ◽  
Feeding Tube ◽  
Intensity Modulated ◽  
End Results

scholarly journals Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis

2019 ◽  
Vol 30 (7) ◽  
pp. 721-732 ◽  
Author(s):  
Jennifer A. Schlichting ◽  
Nitin A. Pagedar ◽  
Catherine Chioreso ◽  
Charles F. Lynch ◽  
Mary E. Charlton
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Surveillance ◽  
Patterns Of Care ◽  
Treatment Trends ◽  
End Results

scholarly journals Age alone is not a barrier to concurrent chemoradiotherapy for advanced head and neck cancer

2021 ◽  
Author(s):  
Gerard Sexton ◽  
Paul Walsh ◽  
Frank Moriarty ◽  
James O'Neill
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Registry ◽  
Neck Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Statistical Significance ◽  
Adult Population ◽  
Multivariate Regression Analysis ◽  
Cancer Registry Data ◽  
Significant Survival

Objectives To evaluate the benefits imparted by concurrent chemoradiotherapy (CCRT) and chemotherapy of any form to elderly head and neck cancer (HNC) patients in Ireland. Secondary outcomes included comparison of these benefits to the adult population and subgroup analysis by site. Design, setting, and participants A retrospective cohort study was conducted using 20 years of cancer registry data provided by the National Cancer Registry of Ireland. All HNC diagnosed from 1994-2014 were included. Cox multivariate regression analysis was applied to test for the benefits of CCRT and chemotherapy of any form in HNC. The primary outcome measures were cancer-specific and all-cause survival in months. Results Survival analysis showed an overall benefit to the use of CCRT in patients with advanced disease over 65 years, particularly when used for hypopharyngeal, oral cavity, oropharyngeal, and laryngeal malignancy, though the latter did not achieve statistical significance. Chemotherapy of any form conferred a survival benefit in elderly patients with hypopharyngeal, laryngeal, nasopharyngeal, and oropharyngeal cancer. Conclusion CCRT and chemotherapy of any form confer significant survival benefits to appropriately selected elderly HNC patients and should therefore not be withheld solely on the basis of age.

scholarly journals Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone

2021 ◽  
Author(s):  
Teresa Magnes ◽  
Sandro M. Wagner ◽  
Thomas Melchardt ◽  
Lukas Weiss ◽  
Gabriel Rinnerthaler ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Registry ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Patient Characteristics ◽  
High Dose ◽  
Radiotherapy Alone

Summary Background The addition of cisplatin or cetuximab to radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) has significantly improved the outcome. While the superiority of cisplatin over cetuximab in combination with radiotherapy has been shown in a definitive setting, we set out to compare postoperative chemoradiotherapy with cisplatin to radioimmunotherapy with cetuximab and radiotherapy alone within the Austrian head and neck cancer registry of the Working Group on Pharmaceutical Tumor Treatment (AGMT) study group. Material and methods In the AGMT head and neck cancer registry, data of 557 patients with SCCHN from five Austrian cancer centers were prospectively collected between 2012 and 2017. Of these patients 120 received postoperative chemoradiotherapy with cisplatin, 26 patients received postoperative radioimmunotherapy with cetuximab and 56 patients were treated with adjuvant radiotherapy only. Patient characteristics, stage of disease, details on treatment as well as survival were analyzed by a chart-based review. Results In patients treated with postoperative radiotherapy the addition of cisplatin significantly improved progression-free survival (PFS) and overall survival (OS) compared to cetuximab (PFS 84.2 months vs. 17.0 months, p = 0.04, OS not reached vs. 46.0 months, p = 0.02) and PFS compared to radiotherapy alone (PFS 84.2 months vs. 28.5 months, p < 0.01). Patients treated with cetuximab were significantly older and had a worse performance score than patients receiving cisplatin or radiotherapy alone. Conclusion This study confirmed the importance of multimodal treatment concepts in patients with locally advanced SCCHN. Postoperative cetuximab might be an option in patients not eligible for high-dose cisplatin but cisplatin should remain the standard of care.

Treatment delay associated with alternative medicine use among veterans with head and neck cancer

Head & Neck ◽  
2006 ◽  
Vol 28 (10) ◽  
pp. 926-931 ◽  
Author(s):  
Greg E. Davis ◽  
Chris L. Bryson ◽  
Bevan Yueh ◽  
Mary B. McDonell ◽  
Mark A. Micek ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Alternative Medicine ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Delay ◽  
Medicine Use
Sign in / Sign up

Export Citation Format

Share Document